Cambrian Biopharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic

 Cambrian Biopharma, a multi-asset longevity biotech, today announced the close of an oversubscribed Series C financing, which raised $100 million. The financing was co-led by Anthos Capital and SALT Fund, with participation from existing investors Apeiron Investment Group, Future Ventures, Moore Capital and others, to develop therapeutics to combat the biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan. With this financing, Cambrian has raised approximately $160 million since the company was founded in 2019.